Sensorineural hearing loss (SNHL) does not recover and only few exceptions exist. It is mostly due to the reason that hair cells in the cochlea cannot regenerate once damaged. Therefore, clinical approaches for SNHL mostly rely on the implantable or external device to deliver sound to brain. Despite the advance of technology, current strategy does not replicate the sound perception of naïve inner ear. To overcome this issue, novel trials to protect or rescue hair cells from the ototoxic insults are investigated. One of these is gene therapy. Protective gene therapy has been applied to several ototoxic insults, but some trials have shown negative effect. Gene therapy using neurotrophin, one of the growth factor, has been expected to show protective effect against acoustic overexposure. But unregulated and untargeted expression of Ntf3 revealed adverse effect showing deterioration of nerve ending and synapse. Meanwhile, gene therapies have been adopted and tried for cisplatin ototoxicity. Most of the studies has been shown promising outcome. Also several studies have shown protective effect of gene therapy for aminoglycoside ototoxicity. Recent publication showed that heat-shock protein 70 was effective in preventing aminoglycoside ototoxicity. Furthermore, use of gene therapy expands to the field of cochlear implant, in which it can be used as an enhancer of treatment outcome. Application of neurotrophins resulted in increase of spiral ganglion densities as well as migration of peripheral nervous fibers to the location which would be closer to the electrode when implanted.

